Novartis (NVS)
Novartis Cash and ST Investments: 5.388B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
NVS Cash and ST Investments Rankings
| Overall | 96th percentile | 140 of 4371 |
| Sector | 97th percentile | 11 of 504 in Healthcare |
| Industry | 72nd percentile | 7 of 25 in Drug Manufacturers - Major |
NVS Cash and ST Investments Range, Past 5 Years
| Minimum | 5.075B | Dec 2011 |
| Maximum | 23.00B | Jun 2010 |
| Average | 10.86B |
About Cash and Short Term Investments
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities
Learn More
You may also be interested in these NVS related companies
NVS News
Blueberries, Gold Bond, Ovaltine and Obesity: The Makings for a Very Good Story
May 23, 5:03PM Benzinga
May 23, 5:03PM Benzinga
Perrigo (PRGO) Gets Final FDA Approval for Generic Prevacid Caps (NVS)
May 18, 1:36PM Street Insider
May 18, 1:36PM Street Insider
Novartis (NVS) Updates on Lucentis; Shows Encouraging Results in DME Patients
May 10, 7:45AM Street Insider
May 10, 7:45AM Street Insider
$SQNM 1 competitor down: $NVS : Fluidigm, Novartis End Pact Aimed at Non-invasive Fetal Diagnostic Test $ILMN $GNOM
about 23 days ago by biotech
about 23 days ago by biotech
$NVS FDA approved Afinitor for treatment of adult patients w kidney tumors who do not require immediate surgery. http://stks.co/3XkB
about 34 days ago by abubnic
about 34 days ago by abubnic
News related to $NVS: 'New J&J CEO plans realistic, optimistic future' http://stks.co/3Vvz
about 35 days ago by TradeBot
about 35 days ago by TradeBot
$NVS http://stks.co/3Rts WEEKLY. Breakout appears imminent on this Swiss drug maker. Yields 4.4%
about 39 days ago by dv0x
about 39 days ago by dv0x
@HighRiskBuyer $ARNA $NVS $VNDA $ONXX $DNDN $KERX nothing earlier, Looks like he made up his own false rumors.
about 41 days ago by jackofalltrade
about 41 days ago by jackofalltrade
@natesadeghi Be careful what you focus in on. $AMLN (Byetta & Bydureon) continues to take market share away from Victoza $NVS
about 44 days ago by jackofalltrade
about 44 days ago by jackofalltrade
$TARO shareholders sign this online petition if u agree..will be sent to Taro BOD $TEVA $PFE $NVIV $NVS $AGEN $PRGO http://stks.co/3L8b
about 47 days ago by imhobutdydd
about 47 days ago by imhobutdydd
Quick Pitch: Long on $AZN Target Price: $62 http://stks.co/3Jz7 $SNY $NVS "Best downside protection among Pharma large caps"
about 48 days ago by SumZero
about 48 days ago by SumZero
- $NVS - any ideas on how the recall will affect nvs Q1 earnings repo
about 49 days ago by SCPlunger
about 49 days ago by SCPlunger
Wal-Mart’s Great Dividend Story: Cash Flow Monster Shares the Wealth http://stks.co/3GsC $WMT $AZN $GSK $NVS $MRK $BMY $PFE
about 51 days ago by ycharts
about 51 days ago by ycharts
$IDIX IMHO there won't be possibility of M&A until 184 is proven to work in clinical trials, see $GILD. Only then maybe, if $NVS allows.
about 63 days ago by lindaheart
about 63 days ago by lindaheart
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NVS | 52.00 | -0.26 | -0.49% | 125.77B |
| NVR | 800.47 | -33.73 | -4.04% | 4.221B |
| NVO | 135.80 | -2.83 | -2.04% | 80.41B |
| NVMI | 7.00 | +0.00 | +0.00% | 183.89M |
| NVLS | 42.29 | -1.21 | -2.78% | 3.080B |
| NVJ | 15.54 | -0.05 | -0.30% | |
| NVEC | 51.74 | -1.01 | -1.91% | 254.26M |
| NVE | 17.09 | -0.16 | -0.93% | 4.071B |
| NVDA | 12.54 | -0.18 | -1.42% | 7.857B |
| NVAX | 1.235 | -0.04 | -3.52% | 155.61M |
